Patient #1 Video
Length: 2:30
Patient #2 Video
Length: 2:43
Patient #3 Video
Length: 3:03
Patient #4 Video
Length: 2:49
Patients in these videos had varying responses to AMPYRA.
Footnotes:
*Poll commissioned by Acorda Therapeutics, Inc. and the Multiple Sclerosis Association of America. February 21, 2008.
**Harris Interactive. Poll commissioned by Acorda Therapeutics, Inc. and the National MS Society. June 10-17, 2011.
About the videos:
These videos show actual patients with MS who were prescribed AMPYRA. The videos were recorded during healthcare provider office visits.
Not all patients have increased walking speed when treated with AMPYRA as seen in the patient 4 video.
Walking impairment affects many people with MS
- 87% of people with MS report some difficulty walking*
- 92% of people with MS who have difficulty walking say it impacts their ability to carry out daily tasks**
The only MS therapy indicated to improve walking
- AMPYRA improved walking speed in significantly more patients than placebo (sugar pill) in 2 clinical trials (34.8% vs. 8.3% and 42.9% vs. 9.3%)
- Patients responding to AMPYRA had an average increase in walking speed of about 25%
Not everyone responds to AMPYRA
- Individual response to AMPYRA may vary
- Talk to your healthcare provider to see if AMPYRA may be right for you
